Citigroup Lowers Hims & Hers Health (NYSE:HIMS) to Neutral

Citigroup cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, Marketbeat reports. The firm currently has $20.00 target price on the stock, up from their prior target price of $16.00. A number of other research […]

Related Keywords

United States ,United Kingdom ,Leerink Partnrs ,Irene Becklund ,Soleil Boughton ,Belpointe Asset Management ,Securities Exchange Commission ,Hims Hers Health Inc ,Citigroup ,Investment Advisers ,Insider Transactions At Hims Hers Health ,Hims Hers Health ,Canaccord Genuity Group ,Hims Hers Health Stock Performance ,News Ratings For Hims Hers Health Daily ,Corton Capital Inc ,Analyst Recommendations For Hims Hers Health ,Hers Health ,Free Report ,Genuity Group ,Res Ptn ,Moderate Buy ,Get Free Report ,Exchange Commission ,Asset Management ,Corton Capital ,Hers Health Daily ,